JP2016505628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505628A5 JP2016505628A5 JP2015553120A JP2015553120A JP2016505628A5 JP 2016505628 A5 JP2016505628 A5 JP 2016505628A5 JP 2015553120 A JP2015553120 A JP 2015553120A JP 2015553120 A JP2015553120 A JP 2015553120A JP 2016505628 A5 JP2016505628 A5 JP 2016505628A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- active agent
- therapeutically active
- adult
- aminoethanesulfonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 10
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 8
- 239000013543 active substance Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 229960003080 taurine Drugs 0.000 claims 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 4
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 4
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 4
- 229960000528 amlodipine Drugs 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 229960005187 telmisartan Drugs 0.000 claims 4
- 108700028369 Alleles Proteins 0.000 claims 3
- 239000005485 Azilsartan Substances 0.000 claims 3
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- 239000005480 Olmesartan Substances 0.000 claims 3
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 claims 3
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 claims 3
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims 3
- 229960002731 azilsartan Drugs 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 229960002198 irbesartan Drugs 0.000 claims 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 3
- 229960004773 losartan Drugs 0.000 claims 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 3
- 229960005117 olmesartan Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 3
- 229960003089 pramipexole Drugs 0.000 claims 3
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 3
- 229960001879 ropinirole Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229960004699 valsartan Drugs 0.000 claims 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 229960002866 duloxetine Drugs 0.000 claims 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 2
- 229960004341 escitalopram Drugs 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- 208000009139 Gilbert Disease Diseases 0.000 claims 1
- 208000022412 Gilbert syndrome Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940100691 oral capsule Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13152170.0 | 2013-01-22 | ||
| EP13152170 | 2013-01-22 | ||
| EP13163915 | 2013-04-16 | ||
| EP13163915.5 | 2013-04-16 | ||
| PCT/EP2014/051098 WO2014114627A1 (en) | 2013-01-22 | 2014-01-21 | Combinations with 2-aminoethanesulfonic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505628A JP2016505628A (ja) | 2016-02-25 |
| JP2016505628A5 true JP2016505628A5 (enExample) | 2017-03-02 |
| JP6655772B2 JP6655772B2 (ja) | 2020-02-26 |
Family
ID=50029001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553120A Active JP6655772B2 (ja) | 2013-01-22 | 2014-01-21 | ２−アミノエタンスルホン酸との組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10918612B2 (enExample) |
| EP (1) | EP2948142B1 (enExample) |
| JP (1) | JP6655772B2 (enExample) |
| WO (1) | WO2014114627A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| MX2019008813A (es) | 2017-01-25 | 2020-02-12 | The George Inst For Global Health | Composiciones para el tratamiento de la hipertension. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4545977A (en) * | 1985-01-11 | 1985-10-08 | G. D. Searle & Co. | Compositions and methods for treating severe acne with isotretinoin |
| US4826679A (en) * | 1986-05-23 | 1989-05-02 | Universite De Montreal | Composition and methods for alleviating cystic fibrosis |
| JPS63132820A (ja) * | 1986-11-22 | 1988-06-04 | Minoru Nakano | 口腔用組成物 |
| US6099869A (en) * | 1995-04-18 | 2000-08-08 | Nutrition 21 | Calcium taurate and antihypertensive drug for hypertension |
| AU703540B2 (en) * | 1996-03-26 | 1999-03-25 | Meddiss, Incorporated | Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general |
| CN100350977C (zh) * | 2001-06-14 | 2007-11-28 | 大塚制药株式会社 | 药物组合物 |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| WO2010089355A1 (en) * | 2009-02-04 | 2010-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| CN102600140A (zh) * | 2012-03-09 | 2012-07-25 | 迪沙药业集团有限公司 | 一种治疗高血压症的组合物 |
-
2014
- 2014-01-17 US US14/157,986 patent/US10918612B2/en active Active
- 2014-01-21 EP EP14701705.7A patent/EP2948142B1/en active Active
- 2014-01-21 JP JP2015553120A patent/JP6655772B2/ja active Active
- 2014-01-21 WO PCT/EP2014/051098 patent/WO2014114627A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2016106150A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2013166781A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2011509252A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2012236849A5 (enExample) | ||
| NZ710575A (en) | Pharmaceutical compositions for the treatment of diabetes mellitus | |
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| JP2012193216A5 (enExample) | ||
| RU2014109074A (ru) | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2019517542A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| JP2015510916A5 (enExample) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| ME02474B (me) | Terapijski režimi | |
| JP2013500977A5 (enExample) | ||
| JP2016512817A5 (enExample) | ||
| HRP20210294T1 (hr) | Postupci liječenja akutnog bubrežnog oštećenja | |
| RU2014129508A (ru) | Новая комбинация | |
| JP2020529995A5 (enExample) |